Kornimate/medical-research-clean huggingface dataset:
ganglion impar denervation and radiofrequency on sacral root 3 for chronic prostatic pain

Conditions: Chronic Pain

Summary: the authors will evaluate the added analgesic benefit of pulsed radiofrequency on sacral root 3 with ganglion impar denervation on chronic pelvic pain due to chronic prostatitis


Eligibility criteria:
inclusion criteria: * patients with chronic pelvic pain due to chronic prostatitis for at least 3 months * vas pain score more than 5 * failed analgesic drug treatment exclusion criteria: * coagulopathy * neurogenic bladder * infection at site of procedure
autologous killer cell therapy in colon cancer patients

Conditions: Colon Cancer Stage IV

Summary: this study aims to evaluate the safety and efficacy of activated and expanded autologous cytokine-killer cells in controlling disease recurrence in colon cancer patients with liver metastasis. 20 patients with confirmed stage iv colon carcinoma with metastasis will be assigned into two groups. patients in both groups will receive the same therapeutic regimen as usual. patients in one group additionally will be treated with a single infusion of autologous killer cells that had been previously prepared from peripheral blood.


Eligibility criteria:
inclusion criteria: * patients with histologically confirmed colorectal cancer at stage iv * ecog performance status 0-2 * adequate cardiac/renal/hepatic function * adequate bone marrow function (blood cell count) exclusion criteria: * patients that have received prior chemotherapy or immune cell therapy * patients that have previously participated in another clinical trial * history of positive test result for hiv, hbv, hcv, htlv-1, syphilis * presence of active infections * patients with immunodeficiencies, autoimmunities, or severe allergies * receiving immunosuppressive regimens
frequency of hypoglycemia in patients with type 2 diabetes under insulin therapy older than 75 years in real life

Conditions: Type2 Diabetes; Elderly; Hypoglycemia

Summary: diabetes is a chronic and progressive disease that affects nearly 3.5 million people in france. currently the investigators are seeing an aging of the population explained by the increase in life expectancy and thus an increasing incidence of diabetes in the elderly. however, the frequency of hypoglycemia in older vulnerable patients remains poorly characterized


Eligibility criteria:
inclusion criteria: * male or female ≥ 75 years of age; * type 2 diabetes for at least 1 year and treated with insulin for at least 6 months; * treated with basal insulin (ie glargine u100: lantus®, abasaglar®, glargine u300: toujeo®, detemir: levemir®, nph), premix (ie novomix® and humalog mix®), and / insulin associated or not with one or more oral and / or injectable antidiabetic agents (analog of glp1...); * benefiting from at least 1 capillary glucose per day (carried out by the patient himself or a caregiver); * benefiting from a standardized geriatric assessment; * signature of informed consent * patient benefiting from a social security system. exclusion criteria: * male or female aged \<75 years; * person without diabetes or type 1 diabetes; * patient treated only lifestyle modifications and / or oral anti-diabetic drugs and / or glp-1 receptor agonists alone; * subjects with secondary or corticosteroid-induced diabetes; * refusal to participate in the study or inability to collect consent; * patient for whom follow-up of the study procedures is impossible (glycemic record impossible or insufficient); * patient not eligible for geriatric assessment; * patient already participating in another study; * patient with a severe pathology limiting his life expectancy (palliative care ...) compromising his participation in the study at the discretion of the investigator; * patient benefiting from a safeguard of justice.

Keywords: type 2 diabetes hypoglycemia elderly insulinotherapy
renal impairment study of pf-06700841

Conditions: Healthy Volunteer; Renal Impairment

Summary: the purpose of this study is to characterize the effect of kidney impairment on the blood concentrations of pf-06700841 and its major metabolite. findings from this study will be used to develop dosing recommendations so that the dose and/or dosing interval may be adjusted appropriately in the presence of kidney disease.

this is a phase 1 non-randomized, open-label, parallel cohort, multi-site study to investigate the effect of renal impairment on the pharmacokinetics, safety and tolerability of pf-06700841 after a single oral dose of 30 mg. subjects will be selected and categorized into normal renal function or renal impairment groups based on their estimated glomerular filtration rate. part 1: a total of approximately 16 subjects will be enrolled; approximately 8 subjects with severe renal impairment and approximately 8 with normal renal function. after statistical evaluation of results from part 1, part 2 may be conducted with approximately 8 subjects each with moderate and mild renal impairment. the total duration of participation from screening visit to day 4 will be a maximum of 32 days and from screening visit to follow-up/contact visit will a maximum of 67 days.

Eligibility criteria:
inclusion criteria: * male or female participants who are between the ages of 18 and 75 years, inclusive, at the screening visit. * body mass index (bmi) of ≥17.5 to ≤40 kg/m2; and a total body weight \>50 kg. * normal, severe, moderate and mild renal function at 2 screening visits. * stable drug regimen exclusion criteria: * renal transplant recipients. * urinary incontinence without catheterization. * subjects with clinically significant infections within the past 6 months prior to first dose of study drug, evidence of active or chronic infection requiring oral treatment within 4 weeks prior to first dose * known history of pulmonary embolism or recurrent deep vein thrombosis * any condition possibly affecting drug absorption (eg, prior bariatric surgery, gastrectomy, ileal resection).

Keywords: pharmacokinetics
reconstruction of acute coracoclavicular ligament disruption with and without tendon graft

Conditions: Acromioclavicular Joint Dislocation

Summary: to evaluate patient function, radiographic changes and complication rates of acute coracoclavicular (cc) joint reconstruction with and without the use of tendon graft as an augmentation to repair.

acromioclavicular (ac) joint dislocations comprise up to 12% of shoulder girdle injuries. many methods of reconstructing the coracoclavicular ligaments, which provide vertical stability of the acromioclavicular joint, have been described. the use of tendon graft to augment the reconstruction provides improved biomechanical stability, less radiographic changes postoperatively including loss of reduction, and improved function. however, the use of a tendon graft necessitates larger drill holes in the clavicle when compared to suture-only repair constructs. the size and placement of these tunnels in the clavicle have been associated with a higher rate of complications. it has been shown that repairs in the setting of acute injury demonstrate less complications including loss of reduction when compared with chronic dislocations. however, other reports describing repair of acute ac joint dislocations without graft augmentation have described significant changes in coracoclavicular distance with routine follow up radiographs, and up to 90% implant migration rates. while use of tendon graft would be expected to provide further stability, they may in turn cause an increased complication rate. 1. to determine complication rates in the reconstruction of ac joint dislocations with and without the use of tendon graft. 2. determine patient satisfaction, the ases, constant, sf-12, sane, sst scores of shoulders that undergo reconstruction of acute ac joint dislocations with and without the use of graft. 3. the investigation aims to determine whether or not graft should be used in the reconstruction of acute ac joint dislocations.

Eligibility criteria:
inclusion criteria: * displaced acromioclavicular joint dislocation sustained within 3 weeks of surgery * recommended for operative fixation * age 18 years or older exclusion criteria: * open dislocation * previous acromioclavicular surgery * unable to follow study protocol * concomitant injury requiring surgery (rotator cuff repair, biceps tenotomy/tenodesis) * active infection * unable to follow postoperative rehabilitation guidelines * reconstruction with coracoclavicular screw or hook plate.

Keywords: shoulder orthopaedics
treatment of post-surgical scars with traditional ablative er:yag versus fractional ablative er:yag

Conditions: Post-Surgical Scars

Summary: the investigators will compare the efficacy of traditional ablative er:yag versus fractional ablative er:yag in a split scar study. the patient will receive a month treatment for 3 months. then follow up for the next 2 months.

background: scars are a common complaint of patients at presentation to a dermatology office. to optimize cosmetic results, the investigators propose to compare erbium-doped yttrium aluminium garnet (er:yag) laser therapy on two different settings: traditional ablative versus fractional ablative. a side to side comparison of split scars will be done to evaluate the two settings. fractionated photothermolysis (fractional setting) has improved the field of laser surgery by allowing the surgery to target microscopic treatment zones (mtz). mtz's allow for cylinders of damage created by laser surgery to be surrounded by normal, unaffected skin. this acts as a reservoir for healing and allows for the microwounds created by laser treatment to heal quickly and with minimal discomfort. objective: to compare efficacy and cosmetic appearance of scars treated with er:yag ablative laser on traditional ablative resurfacing setting versus fractional ablative resurfacing setting. methods: enroll 20 patients for nonsurgical treatment of surgical scars. half of each scar will be treated with the er:yag laser on the traditional ablative setting and the other half of the scar will receive er:yag treatment with the fractional ablative setting. the patients will receive 3 treatments at monthly intervals. they will follow up at 1 and 2 months after the treatment. pictures of the scar will be taken at a 45 degree and 90 degree angle at baseline, before each treatment, after each treatment, and at all follow up appointments. the patients will be blinded as to which side is treated with which laser setting. at the end of the trial, they will be offered the chance to have the side they felt had less improvement treated with the laser device that had been used on the contralateral side of the scar. results: a panel of three blinded dermatologists will evaluate the scar on a well-established five point grading scale for erythema, height and texture, and overall cosmetic outcome. the mean, standard deviation, and kappa values will be calculated. patients will be asked the same scar evaluation questions as the panel as well as their overall satisfaction, how much pain was associated with the procedure, which laser they preferred, and would they recommend treatment to a friend or family member.

Eligibility criteria:
inclusion criteria: * over 8 weeks s/p scar * linear closure * visibly symmetric scar * over 18 years old exclusion criteria: * concomitant treatment of involved skin * propensity for keloid scarring * use of oral retinoids for the past 1 year * pregnancy * immunosuppression * prior laser to the area

Keywords: scar icd-10 cm:l90.5
the correlation between cirrhotic cardiomyopathy and perioperative cardiovascular events in liver transplantation

Conditions: Cirrhosis, Liver

Summary: liver transplantation is an effective treatment for end-stage liver disease. cardiovascular complications are the common causes of death in liver transplant recipients. the presence of cirrhosis cardiomyopathy has a potential impact on the prognosis of liver transplant recipients. therefore, it is important to identify the high risk factors with cirrhotic cardiomyopathy before transplantation, so as to intervene earlier and improve the prognosis of patients.


Eligibility criteria:
inclusion criteria: 1. diagnostic criteria for decompensated liver cirrhosis: according to the guidelines for diagnosis and treatment of liver cirrhosis in 2019; 2. diagnostic criteria for cirrhotic cardiomyopathy: in accordance with the revised criteria of ccm of international multidisciplinary alliance for cirrhotic cardiomyopathy in 2019, the preoperative echocardiographic images of all patients were reviewed, and the systolic and diastolic dysfunction of all patients were evaluated. exclusion criteria: 1. the compensatory liver cirrhosis, primary liver cancer without liver cirrhosis 2. multiple organ transplantation or multiple organ transplantation 3. the preoperative echocardiographic data were not fully recorded, so that the exact diagnosis could not be made 4. there was no follow-up data or baseline data
feasibility of intraoperative microdialysis during neurosurgery for central nervous system malignancies

Conditions: Glioma; Glioblastoma; Metastatic Malignant Neoplasm in the Brain

Summary: this clinical trial evaluates the use of microdialysis catheters during surgery to collect biomarkers, and studies the feasibility of intraoperative microdialysis during neurosurgery for central nervous system malignancies. a biomarker is a measurable indicator of the severity or presence of disease state. information collected in this study may help doctors to develop new strategies to better diagnose, monitor, and treat brain tumors.

primary objective: i. determine biomarkers of in situ gliomas across a diverse patient cohort using intra-operative microdialysis to sample extracellular metabolites. secondary objective: i. evaluate the yield and specificity of microdialysate d-2hg as a candidate tumor biomarker to differentiate between idh-mutated and idh-wildtype gliomas. ii. identify biomarkers of tumor-associated processes including brain edema, brain infiltration with non-enhancing tumor, and tumor-associated hypoxia or necrosis. iii. determine the contribution of blood-brain barrier disruption to metabolite abundance within enhancing gliomas. iv. determine the feasibility of detecting stable-isotope labeled metabolites in human microdialysate. exploratory/correlative objectives: i. perform untargeted metabolomics of tumor microdialysate to elucidate extracellular biomarkers reflective of human central nervous system malignancy subtype, grade, and tumor region. ii. banking of microdialysate specimens for future analyses. outline: patients undergo microdialysis over 30 minutes during standard of care biopsy or resection. after completion of study, patients are followed up for 42 days.

Eligibility criteria:
inclusion criteria: * age \>= 18 years * diagnosis of the following, based on clinical and radiographic evidence: * any glioma * metastatic brain tumor of any primary origin * epileptic focus requiring surgical resection * planned neurosurgical procedure for purposes of biopsy or resection of suspected or previously diagnosed brain tumor (primary or metastatic) or epileptic focus as part of routine clinical care * willing to undergo neurosurgical resection or biopsy at mayo clinic (rochester, minnesota \[mn\]) * ability to understand and the willingness to sign a written informed consent document exclusion criteria: * vulnerable populations: pregnant women, prisoners or the mentally handicapped * patients who are not appropriate candidates for surgery due to current or past medical history or uncontrolled concurrent illness
bacteriophage therapy in tonsillitis

Conditions: Acute Tonsillitis

Summary: the patients received bacteriophage therapy with a liquid piobacteriophage complex (liquid pyobacteriophage complex - pcl). pсl was administered via nebulizer inhalation to irrigate the tonsil mucosa. a total of 5 ml of pcl was inhaled for 10 minutes every 5 days. the drug causes the lysis of certain bacteria, including staphylococcus, enterococcus, streptococcus, enteropathogenic e. coli, proteus vulgaris, proteus mirabilis, pseudomonas aeruginosa, klebsiella pneumoniae and klebsiella oxytoca. the choice of this drug was based on bacteriological studies.

comprehensive outpatient treatment was based on standard clinical guidelines, and symptomatic treatment was performed. on the first day of diagnosis, patients were prescribed complex antibacterial therapy on the basis of possible causative agents. subsequently, antibiotic therapy was adjusted based on the results of the bacteriological examinations. a total of 67 patients received bacteriophage therapy using a liquid complex of pyobacteriophages (pyobacteriophage complex liquid - pсl). pсl was administered via nebulizer inhalation to irrigate the mucous membranes of the tonsils. in total, 5 ml of pcl was inhaled for up to 10 minutes once every 5 days. the drug causes lysis of specific bacteria including staphylococcus, enterococcus, streptococcus, enteropathogenic escherichia coli, proteus vulgaris, proteus mirabilis, pseudomonas aeruginosa, klebsiella pneumoniae, and klebsiella oxytoca. the drug is recommended for use for diseases of the ear, throat, nose, respiratory tract and lungs; inflammation of the sinuses and middle ear; tonsillitis; pharyngitis; laryngitis; tracheitis; bronchitis; pneumonia, pleurisy; and other inflammatory diseases. the choice of this drug was based on bacteriological studies.

Eligibility criteria:
inclusion criteria: * children from 3 to 14 years old. * children with sore throat. * children diagnosed with acute tonsillitis. * children diagnosed with acute respiratory infection (rhinitis, sinusitis, nasopharyngitis). * children with the opportunity to visit the outpatient clinic. * children with the ability to receive inhalation therapy. * children from parents (or guardians) who have given written permission to conduct clinical and laboratory research. exclusion criteria: * children under 3 years old and over 14 years old. * children receiving hospital treatment. * children with acute respiratory tract diseases (bronchitis, pneumonia, pleurisy). * children with сhronic respiratory tract diseases (bronchitis, pneumonia). * children who are allergic to antibiotics. * children with cancer, immunological and hematological diseases. * children with severe psychological illnesses (schizophrenia, mental retardation, etc.) * children with cancer, immunological and hematological diseases. * children with tuberculosis.

Keywords: acute tonsillitis children bacteriophage immunity ambulatory treatment
integrative medicine for hospital workers exposed to war

Conditions: Anxiety

Summary: during the "iron swords" war in israel in 2023, the residents of the gaza strip and the surrounding area, along with the soldiers of the security service, were exposed to a very high intensity of trauma. added to this is an extensive cycle of trauma for those who were directly and indirectly exposed to loss and terror throughout the country. medical teams in the hospitals and in the community were exposed with the highest intensity to these traumatic aspects which were amplified by the collapse of many of the resilience and mental health centers in the south. an integrative medicine treatment clinic was established at the bnai zion medical center for the purpose of providing a response to all hospital employees who are exposed and will be exposed (directly or indirectly) to the wounded and patients expressing trauma, including symptoms of acute stress disorder, as a result of war and terrorism. hospital employees are invited to register for complementary medicine treatments on the hospital's website according to indications that include anxiety, emotional distress and/or typical acute stress disorder (asd) symptoms, including physical distress (such as pain, breathing disorder, digestive system symptoms, exhaustion, etc.). the employees are treated by a team from the system for integrative medicine, including practitioners of acupuncture; touch/movement techniques (for example, qigong, reflexology, shiatsu) or mind-body medicine (for example, relaxation and breathing exercises) and may include one or more of the above 3 treatment areas. in the proposed study, the investigators plan to examine the effect of these treatments on various symptoms experienced by hospital employees during this period.


Eligibility criteria:
inclusion criteria: * hospital employees * anxiety, emotional distress and/or typical asd symptoms directly or indirectly related to exposure to the trauma of terrorism or war exclusion criteria: * none

Keywords: acute stress disorder anxiety integrative medicine hospital workers war
clinical trial of stahist in seasonal allergic rhinitis (sar) subjects

Conditions: Seasonal Allergic Rhinitis

Summary: to report and compare total symptom scores, nasal symptom scores, post-nasal drip symptom scores, and adverse reactions in and between sar subjects on active drug and sar subjects on placebo.

this double-blind, placebo-controlled study will evaluate the efficacy and safety of stahist vs. placebo over a 2-week period in 100 study subjects with a history of sar for at least two years. the study will take place in two sites, louisville, ky and south bend, in. sar symptoms to be scored and compared include: nasal congestion, rhinorrhea, nasal itching, sneezing, and post-nasal drip.

Eligibility criteria:
inclusion criteria: 1. males and females of any ethnic group between 18 and 60 years of age. 2. history of moderate to severe sar for at least two years. 3. subjects' symptoms resulting from the irritation of sinus, nasal and upper respiratory tract tissues will include the five symptoms that are th focus of this study: nasal congestion, rhinorrhea, nasal itching, sneezing, and post-nasal drip. subjects must have a tss baseline score of at least 8 on the s5 subject diary. 4. prior to study drug administration, subjects' good health will be confirmed by medical history and physical examination, including pregnancy test (urine dip) before study inception. 5. allergic hypersensitivity will be confirmed by the physician or well established patient medical history. 6. subject's compliance with requisite run-in period for each subject will be confirmed by investigator/designee. exclusion criteria: 1. pregnancy or lactation. 2. immunotherapy unless at a stable maintenance dose. 3. presence of a medical condition that might interfere with treatment evaluation or require a change in therapy including but not limited to high blood pressure or urinary retention problems. 4. alcohol dependence. 5. use of any other investigational drug in the previous month. 6. subjects presenting with asthma requiring corticosteroid treatment. 7. subjects with multiple drug allergies. 8. subjects known to have an idiosyncratic reaction to any of the ingredients in imp (stahist). 9. subject who is participating in any other clinical study. 10. subject who is unable to meet washout requirements. 11. subject with clinically significant abnormal vital sign or laboratory value that precludes participation. 12. subject with any family relationship to the sponsor, investigator, or staff of sponsor or investigator. 13. a uri within 4 weeks of study inception. 14. subjects taking beta blockers or try-cyclic antidepressants. -

Keywords: phase 2 sar stahist